Disparities Remain in Prevalence of Cancer Screening Tests

Share this content:
Researchers found disparities in the prevalence of test use among subgroups for all tests examined.
Researchers found disparities in the prevalence of test use among subgroups for all tests examined.

(HealthDay News) -- There are persistent disparities in recommended cancer screening tests among U.S. adults, particularly among the uninsured, according to a study published online July 26 in the U.S. Centers for Disease Control and Prevention's Preventing Chronic Disease.

Ingrid J. Hall, Ph.D., M.P.H., from the CDC in Atlanta, and colleagues used 2000 to 2015 data from the National Health Interview Survey to examine trends in the prevalence of cancer screening that adhered to U.S. Preventive Services Task Force screening recommendations.

The researchers found that over the study period, colorectal cancer screening was the only test that increased. There were disparities in the prevalence of test use among subgroups for all tests examined. No contact with a doctor in the past year, no usual source of health care, and no insurance coverage were associated with reduced use of screening tests.

"Understanding use of cancer screening tests among different population subgroups is vital for planning public health interventions with potential to increase screening uptake and reduce disparities in cancer morbidity and mortality," the authors write.

Abstract/Full Text

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs